Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus

被引:94
作者
Artz, MA
Boots, JMM
Ligtenberg, G
Roodnat, JI
Christiaans, MHL
Vos, PF
Blom, HJ
Sweep, FCGJ
Demacker, PNM
Hilbrands, LB
机构
[1] Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Maastricht, Med Ctr, Dept Nephrol, Maastricht, Netherlands
[3] Univ Utrecht, Dept Nephrol, Med Ctr, Utrecht, Netherlands
[4] Univ Rotterdam, Dept Nephrol, Med Ctr, Rotterdam, Netherlands
[5] Univ Nijmegen, Med Ctr, Dept Clin Biochem, Nijmegen, Netherlands
[6] Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, Nijmegen, Netherlands
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷 / 07期
关键词
D O I
10.1097/01.ASN.0000071515.27754.67
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cyclosporine is considered to contribute to the high cardiovascular morbidity and mortality in patients after renal transplantation. Tacrolimus may be more favorable in this respect, but controlled data are scarce. In this prospective randomized study in 124 stable renal transplant patients, the effects of conversion from cyclosporine to tacrolimus on cardiovascular risk factors and renal function were investigated. Follow-up was 6 mo. Statistical analysis was performed by ANOVA for repeated measurements. The serum creatinine level decreased from 137 +/- 30 mumol/L to 131 +/- 29 mumol/L (P < 0.01). Three months after conversion from cyclosporine to tacrolimus, mean BP significantly decreased from 104 +/- 13 to 99 +/- 12 mmHg (P < 0.001). Serum LDL cholesterol decreased from 3.48 +/- 0.80 to 3.11 +/- 0.74 mmol/L (P < 0.001) and serum apolipoprotein B decreased from 1018 +/- 189 to 935 +/- 174 mg/L (P < 0.001). Serum triglycerides decreased from 2.11 +/- 1.12 to 1.72 +/- 0.94 mmol/L (P < 0.001). In addition, both rate and extent of LDL oxidation were reduced. The fibrinogen level decreased from 3638 +/- 857 to 3417 +/- .751 mg/L (P < 0.05). Plasma homocysteine concentration did not change. Three months after conversion, plasma fasting glucose level temporarily increased from 5.4 +/- 1.3 mmol/L to 5.8 +/- 1.9 mmol/L (P < 0.05). Conversion to tacrolimus resulted in a significant reduction of the Framingham risk score. In conclusion, conversion from cyclosporine to tacrolimus in stable renal transplant patients has a beneficial effect on renal function, BP, serum concentration and atherogenic properties of serum lipids, and fibrinogen.
引用
收藏
页码:1880 / 1888
页数:9
相关论文
共 50 条
  • [31] Diabetes mellitus after renal transplantation - As deleterious as non-transplant-associated diabetes?
    Miles, AMV
    Sumrani, N
    Horwitz, R
    Homel, P
    Maursky, V
    Markell, MS
    Distant, DA
    Hong, JH
    Sommer, BG
    Friedman, EA
    [J]. TRANSPLANTATION, 1998, 65 (03) : 380 - 384
  • [32] LOW-DENSITY-LIPOPROTEIN STIMULATES THE EXPRESSION OF MACROPHAGE-COLONY-STIMULATING FACTOR IN GLOMERULAR MESANGIAL CELLS
    PAI, RM
    KIRSCHENBAUM, MA
    KAMANNA, VS
    [J]. KIDNEY INTERNATIONAL, 1995, 48 (04) : 1254 - 1262
  • [33] Peschke B, 1999, CLIN NEPHROL, V51, P290
  • [34] A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
    Pirsch, JD
    Miller, J
    Deierhoi, MH
    Vincenti, F
    Filo, RS
    [J]. TRANSPLANTATION, 1997, 63 (07) : 977 - 983
  • [35] Immunosuppression enhances atherogenicity of lipid profile after transplantation
    Quaschning, T
    Mainka, T
    Nauck, M
    Rump, LC
    Wanner, C
    Krämer-Guth, A
    [J]. KIDNEY INTERNATIONAL, 1999, 56 : S235 - S237
  • [36] OXIDATIVELY MODIFIED LOW-DENSITY LIPOPROTEINS - A POTENTIAL ROLE IN RECRUITMENT AND RETENTION OF MONOCYTE MACROPHAGES DURING ATHEROGENESIS
    QUINN, MT
    PARTHASARATHY, S
    FONG, LG
    STEINBERG, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (09) : 2995 - 2998
  • [37] STEINBERG D, 1989, NEW ENGL J MED, V320, P915
  • [38] Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis
    Strauss, BH
    Lau, HK
    Bowman, KA
    Sparkes, J
    Chisholm, RJ
    Garvey, MB
    Fenkell, LL
    Natarajan, MK
    Singh, I
    Teitel, JM
    [J]. CIRCULATION, 1999, 100 (15) : 1616 - 1622
  • [39] METABOLIC BASIS OF HYPERAPOBETALIPOPROTEINEMIA - TURNOVER OF APOLIPOPROTEIN-B IN LOW-DENSITY-LIPOPROTEIN AND ITS PRECURSORS AND SUBFRACTIONS COMPARED WITH NORMAL AND FAMILIAL HYPERCHOLESTEROLEMIA
    TENG, B
    SNIDERMAN, AD
    SOUTAR, AK
    THOMPSON, GR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (03) : 663 - 672
  • [40] TEPOELEPOTHOFF MT, 1995, ANN CLIN BIOCHEM, V32, P20